Relevance of posttransplant HLA-Ii antibodies production on long-term survival of renal allograft
Liu, Z.-h.; Shen, B.; Tan, J.-m.; Ding, Y.-d.
Zhonghua Yi Xue Za Zhi 87(28): 1978-1980
2007
ISSN/ISBN: 0376-2491 PMID: 17923038 Document Number: 614361
To evaluate the clinic relevance of anti-HLA-II antibodies on allograft long-term survival. Perioperative sera of 118 cadaveric kidney recipients were tested by ELISA for anti-HLA-II antibodies in our prospective cohort study. All recipients who divided into different groups according to HLA antibody production were followed-up. (1) Anti-HLA-II antibody-positive recipients were associated with significantly lower graft survival (78.6% vs 84.4%; 71.4% vs 80.0%; P = 0.002) and death-censored graft survival (85.7% vs 92.2%; 82.1% vs 90.0%; P = 0.003) at 3 and 4 years compared to antibody-negative recipients. (2) Anti-HLA-II antibody-positive recipients were associated with a significantly increased risk for decline in renal function at 3 and 4 years (39.3% vs 33.3%; 46.4% vs 38.9%, P = 0.001). (3) There was statistically non-significance difference in late-acute rejection rate between two groups (10.7% vs 13.3%, P > 0.05). Posttransplant HLA-II antibodies perhaps are one of the most important influential facts on allograft long-term survival and could be used to predict the prognosis of allograft.